trending Market Intelligence /marketintelligence/en/news-insights/trending/nqidyzmy6asmdafxmhktya2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Amid probe, Chinese inspectors find no quality issues at 45 vaccine companies

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Amid probe, Chinese inspectors find no quality issues at 45 vaccine companies

China's State Drug Administration has found no quality or safety problems at 45 vaccine companies during inspections spurred by the discovery of serious irregularities at one vaccine maker, state-owned Xinhua News reported.

In July, a surprise inspection of Shenzhen-listed Changsheng Bio-Technology Co. Ltd. found serious irregularities, including the fabrication of production records in the manufacturing of rabies vaccines. Chinese President Xi Jinping ordered a thorough investigation into the matter, and the State Drug Administration launched inspections of other vaccine manufacturers in the country.

Xinhua, citing information posted on the State Drug Administration's website, reported Sept. 7 that 38 vaccine makers were found to be in compliance with good manufacturing practices and were meeting other rules and regulations. The remaining companies had halted vaccine production for more than three years and therefore were not selling products into the marketplace.

The vaccine safety inspections were conducted between July 23 and Aug. 9, Xinhua reported. During these checks, the inspectors thoroughly examined the companies' facilities and laboratory controls, materials, production and quality management.

The state agency plans to step up efforts on vaccine quality supervision to detect and remove safety hazards faster, Xinhua said. The regulator will also ensure that local drug authorities initiate routine supervision on vaccine manufacturers to ensure they abide by regulations.